JP2022523819A5 - - Google Patents

Info

Publication number
JP2022523819A5
JP2022523819A5 JP2021552742A JP2021552742A JP2022523819A5 JP 2022523819 A5 JP2022523819 A5 JP 2022523819A5 JP 2021552742 A JP2021552742 A JP 2021552742A JP 2021552742 A JP2021552742 A JP 2021552742A JP 2022523819 A5 JP2022523819 A5 JP 2022523819A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
oil
pharmaceutically acceptable
abiraterone
decanoate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021552742A
Other languages
English (en)
Japanese (ja)
Other versions
JP7644713B2 (ja
JP2022523819A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/020915 external-priority patent/WO2020180942A1/en
Publication of JP2022523819A publication Critical patent/JP2022523819A/ja
Publication of JP2022523819A5 publication Critical patent/JP2022523819A5/ja
Application granted granted Critical
Publication of JP7644713B2 publication Critical patent/JP7644713B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021552742A 2019-03-06 2020-03-04 アビラテロンプロドラッグ Active JP7644713B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962814568P 2019-03-06 2019-03-06
US62/814,568 2019-03-06
US201962849259P 2019-05-17 2019-05-17
US62/849,259 2019-05-17
PCT/US2020/020915 WO2020180942A1 (en) 2019-03-06 2020-03-04 Abiraterone prodrugs

Publications (3)

Publication Number Publication Date
JP2022523819A JP2022523819A (ja) 2022-04-26
JP2022523819A5 true JP2022523819A5 (cg-RX-API-DMAC7.html) 2023-03-09
JP7644713B2 JP7644713B2 (ja) 2025-03-12

Family

ID=70190090

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021552742A Active JP7644713B2 (ja) 2019-03-06 2020-03-04 アビラテロンプロドラッグ

Country Status (15)

Country Link
US (4) US10792292B2 (cg-RX-API-DMAC7.html)
EP (2) EP4286006A3 (cg-RX-API-DMAC7.html)
JP (1) JP7644713B2 (cg-RX-API-DMAC7.html)
KR (1) KR102879575B1 (cg-RX-API-DMAC7.html)
CN (3) CN114026106B (cg-RX-API-DMAC7.html)
AU (1) AU2020232706B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021017377A2 (cg-RX-API-DMAC7.html)
CA (1) CA3131034A1 (cg-RX-API-DMAC7.html)
DK (1) DK3935068T3 (cg-RX-API-DMAC7.html)
ES (1) ES2964818T3 (cg-RX-API-DMAC7.html)
IL (1) IL286048B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021010553A (cg-RX-API-DMAC7.html)
PL (1) PL3935068T3 (cg-RX-API-DMAC7.html)
WO (1) WO2020180942A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202107278B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114026106B (zh) 2019-03-06 2025-01-21 普洛拉治疗公司 阿比特龙前药
US12347562B2 (en) * 2019-12-26 2025-07-01 Cerner Innovation, Inc. Decision support application for PCOS
AU2021338271A1 (en) * 2020-09-02 2023-03-30 Astellas Us Llc Abiraterone prodrugs
CN113929727A (zh) * 2020-09-28 2022-01-14 南京易腾药物研究院有限公司 阿比特龙酯类衍生物及其制备方法和应用
CN117120034A (zh) * 2021-02-15 2023-11-24 普洛佩拉治疗公司 阿比特龙前药
CN113061154B (zh) * 2021-03-25 2022-07-08 天津海润家和创新医药研究有限责任公司 新型注射用阿比特龙衍生物的制备方法和用途
CN113527401A (zh) * 2021-08-26 2021-10-22 雷昊言 一种阿比特龙前体化合物及其制备方法和应用
WO2023038933A1 (en) * 2021-09-08 2023-03-16 Propella Therapeutics, Inc. Oral abiraterone formulations
CN119136813A (zh) * 2022-03-01 2024-12-13 普洛拉治疗公司 阿比特龙前药
WO2024107928A1 (en) * 2022-11-16 2024-05-23 Propella Therapeutics, Inc. Abiraterone decanoate composition and use in therapy
CN116046950A (zh) * 2023-01-18 2023-05-02 河北省药品医疗器械检验研究院(河北省化妆品检验研究中心) 一种检测醋酸阿比特龙中5种杂质的方法
LU506495B1 (en) * 2024-03-01 2025-09-01 Alfasan Nederland B V 17alpha-HYDROXYLASE/17,20-LYASE (CYP17A1) INHIBITORS FOR THE TREATMENT OF SPONTANEOUS HYPERADRENOCORTICISM IN DOGS
WO2026130540A1 (zh) * 2024-12-20 2026-06-25 长春金赛药业有限责任公司 一种阿比特龙衍生物、药物组合物及其制备方法和应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
WO2003075958A1 (fr) 2002-03-11 2003-09-18 Takeda Chemical Industries, Ltd. Medicaments permettant de traiter une maladie dependant d'une hormone sexuelle
JP2004002321A (ja) * 2002-03-11 2004-01-08 Takeda Chem Ind Ltd 性ホルモン依存性疾患治療剤
TW200404552A (en) 2002-05-30 2004-04-01 Akzo Nobel Nv Self administered contraception
GB0418900D0 (en) * 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
CN102772358A (zh) 2005-06-16 2012-11-14 美瑞德生物工程公司 药物组合物及其用途
HRP20130961T1 (hr) 2006-08-25 2013-11-22 Janssen Oncology, Inc. Kombinacije za tretman raka
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US20090124587A1 (en) 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
GB2479693B (en) 2009-02-05 2014-04-09 Tokai Pharmaceuticals Inc Steroidal CYP17 inhibitors and their use in the treatment of cancer and prostate hyperplasia
EP2393827B1 (en) * 2009-02-05 2015-10-07 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
WO2011066582A1 (en) 2009-11-30 2011-06-03 Harbor Biosciences, Inc. Anticancer compounds and screening method
WO2011083830A1 (ja) 2010-01-06 2011-07-14 学校法人関西文理総合学園 新規抗がん剤およびそのスクリーニング方法
BR112013017635A2 (pt) 2010-12-16 2016-10-11 Biomarin Pharm Inc inibidores de cyp11b, cyp17 e/ou cyp21
DE102011083725A1 (de) 2011-09-29 2013-04-04 Bayer Pharma AG Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
CN104066744B (zh) 2011-10-10 2017-03-22 扎克系统公司 用于制备17‑取代的甾体的方法
MX367640B (es) 2011-11-30 2019-08-29 Astrazeneca Ab Tratamiento combinado del cáncer.
AU2012358219A1 (en) 2011-12-22 2014-07-10 Tokai Pharmaceuticals, Inc. Methods and compositions for combination therapy using P13K/mTOR inhibitors
US20140079636A1 (en) 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
WO2013159225A1 (en) 2012-04-23 2013-10-31 Alphora Research Inc. Process for preparation of 17-substituted steroids
WO2014009434A1 (en) 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
WO2014016830A1 (en) 2012-07-25 2014-01-30 Mapi Pharma Ltd. Process and intermediates for the preparation of abiraterone acetate
US20140011992A1 (en) 2012-12-20 2014-01-09 Crystal Pharma, S.A.U. Synthesis of abiraterone and related compounds
EP2945628B1 (en) 2013-01-15 2020-04-15 Aragon Pharmaceuticals, Inc. Androgen receptor modulator in combination with abiraterone acetate and prednisone for treating prostate cancer
CA2898573A1 (en) 2013-01-18 2014-07-24 Cortendo Ab (Publ) Abiraterone and analogs thereof for the treatment of diseases associated with cortisol overproduction
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
TWI686212B (zh) 2013-03-15 2020-03-01 阿聯商太陽法瑪全球有限公司 醋酸阿比特龍配方
EP3738594A1 (en) 2013-09-10 2020-11-18 Madrigal Pharmaceuticals, Inc. Targeted therapeutics having an hsp90 ligand as binding moiety
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
MX2016004267A (es) 2013-10-01 2016-07-08 Novartis Ag Combinacion.
JP6576942B6 (ja) 2014-03-03 2019-11-27 マドリガル ファーマシューティカルズ インコーポレイテッド 標的治療薬
MA39483A (fr) 2014-03-18 2015-09-24 Synta Pharmaceuticals Corp Agents thérapeutiques cibles
CN104017045B (zh) * 2014-06-23 2016-01-13 广州艾格生物科技有限公司 甾体cyp17抑制剂的新型药物前体及其应用、制备方法
US9937259B2 (en) 2014-06-27 2018-04-10 Zhuhai Beihai Biotech Co., Ltd. Abiraterone derivatives and non-covalent complexes with albumin
WO2016044701A1 (en) 2014-09-18 2016-03-24 Iceutica Inc. Abiraterone acetate formulation and methods of use
CN104356191A (zh) 2014-09-29 2015-02-18 上海延安药业(湖北)有限公司 阿比特龙单琥珀酸酯及其制备方法
CN106061990B (zh) 2014-11-28 2019-09-10 四川海思科制药有限公司 一种阿比特龙衍生物及其制备方法和医药用途
CN104447394B (zh) * 2014-12-17 2017-01-18 成都傲飞生物化学品有限责任公司 一种乌苯美司的新型合成工艺
CN104710499A (zh) 2015-02-15 2015-06-17 重庆医药工业研究院有限责任公司 一种丙酸阿比特龙的晶型及其制备方法
CN108112235A (zh) 2015-03-06 2018-06-01 克利夫兰临床基金会 改变类固醇代谢以用于治疗类固醇依赖性疾病
ES2954596T3 (es) * 2015-12-23 2023-11-23 Univ British Columbia Profármacos unidos a lípidos
JP6842474B2 (ja) 2016-02-02 2021-03-17 深▲セン▼市塔吉瑞生物医▲薬▼有限公司Shenzhen TargetRx,Inc. ステロイド系化合物、当該化合物を含む組成物及びその使用
US12128113B2 (en) 2016-05-18 2024-10-29 Modernatx, Inc. Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
US10717762B2 (en) 2016-10-11 2020-07-21 Zhuhai Beihai Biotech Co., Ltd. Abiraterone derivative and formulations thereof
CN106977577A (zh) 2017-04-21 2017-07-25 湖南师范大学 两类阿比特龙衍生物的合成
JP2022523704A (ja) 2019-01-25 2022-04-26 シェンチェン・ファーマシン・カンパニー・リミテッド 医薬組成物
CN114026106B (zh) 2019-03-06 2025-01-21 普洛拉治疗公司 阿比特龙前药
CN113825514A (zh) 2019-03-18 2021-12-21 分散技术有限责任公司 阿比特龙-环状寡聚体药物制剂及其形成和施用方法
AU2021338271A1 (en) 2020-09-02 2023-03-30 Astellas Us Llc Abiraterone prodrugs
CN113929727A (zh) 2020-09-28 2022-01-14 南京易腾药物研究院有限公司 阿比特龙酯类衍生物及其制备方法和应用
CN117120034A (zh) 2021-02-15 2023-11-24 普洛佩拉治疗公司 阿比特龙前药
WO2023038933A1 (en) 2021-09-08 2023-03-16 Propella Therapeutics, Inc. Oral abiraterone formulations

Similar Documents

Publication Publication Date Title
IL286048B1 (en) Abiraterone decanoate and pharmaceutically acceptable salts thereof, pharmaceutical compsitions comprising the same, uses and preparation thereof
US9388210B2 (en) Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
TWI641616B (zh) 阿比特龍衍生物及其製備方法和醫藥用途
JP2024506382A5 (cg-RX-API-DMAC7.html)
US11111227B2 (en) Rotigotine behenate, and manufacturing method and application thereof
US20030092638A1 (en) Protopanaxadiol and protopanaxatriol and their use as anti-cancer agents
JP2019514955A (ja) 選択的エストロゲン受容体ダウンレギュレーター(serds)
WO2014127201A1 (en) Neuroactive enantiomeric 15-, 16- and 17-substituted steroids as modulators for gaba type-a receptors
JP2018138594A (ja) オナプリストン多形体及び使用方法
JP2021522306A (ja) ブプレノルフィン誘導体の長時間作用性注射製剤および結晶形
CN113929727A (zh) 阿比特龙酯类衍生物及其制备方法和应用
JP2014516078A (ja) 新規なタッカロノリド微小管安定剤
JPS6341887B2 (cg-RX-API-DMAC7.html)
CA2626627C (en) Androsterone derivatives and method of use thereof
RU2021128701A (ru) Пролекарства абиратерона
AU2004243500A1 (en) Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
WO2014169462A1 (zh) 具有抗癌活性的7-α-[9-(4,4,5,5,-五氟戊基亚硫酰基)壬基]-雌甾-1,3,5(10)-三烯-3,17β-二醇的酯类衍生物及其制备方法
US20030069215A1 (en) Methods of making and using 7a,11b-dimethyl-17b-hydroxy-4-estren-3-one 17b-trans-4-n-butylcyclohexane carboxylate and 7a,11b-dimethyl-17b-hydroxyestr-4-en-3-one 17-undecanoate
TW200904451A (en) Progesterone-receptor antagonist for use in BRCA alone or as combination with antiestrogen
CN104997788B (zh) 一种抗抑郁化合物在制备抗抑郁药物和抗抑郁保健食品中的应用
JPH01500111A (ja) 11−デスオキシ−17α−ヒドロキシコルチコステロン誘導体
TW200902028A (en) Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in BRCA mediated diseases
RU2719457C2 (ru) Сложные эфиры стероидного лактама и производных бис(2-хлорэтил)аминофеноксипропановой кислоты
CN103664836B (zh) 7β,10β-二甲氧基多西紫杉醇氘代丙酮合物的晶型A及其制备方法
JPH0240079B2 (cg-RX-API-DMAC7.html)